Zai Lab Ltd., a Shangai, China-based biopharmaceutical company, secured over $100M in Series B financing.
The round was led by Advantech Capital with participation from OrbiMed and existing investors Qiming Ventures, Sequoia Capital China, and TF Capital.
The company intends to use the funds for research and development programs as well as ongoing in-licensing and commercialization efforts.
Led by Dr. Samantha Du, founder, Chairman and CEO, Zai Lab focuses on discovering, developing and commercializing a pipeline comprised of antibody-based therapies and other protein-based therapeutics that modulates the immune system or directly target tumors.
The company’s programs are specifically aimed at patient populations with high unmet medical need—including many underserved indications specific to the Asian region.
Zai Lab is also backed by Kleiner Perkins Caufield & Byers (KPCB).